Can leukemia-derived dendritic cells generate antileukemia immunity?

Expert Review of Vaccines

Volumn 5, Issue 4, 2006, Pages 467-472

  Rosenblatt, Jacalyn ^a   Avigan, David ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Cancer immunotherapy; Dendritic cell vaccine; Leukemia derived dendritic cell

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD14 ANTIGEN; CD28 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MELANOMA ANTIGEN; MUCIN 1; MYELOBLASTIN; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR WT 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL CLONE; CELL DIFFERENTIATION; CELL FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; ECZEMA; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LEUKEMIA DERIVED DENDRITIC CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; LEUKEMIA; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE DEPLETION;

EID: 33750337189     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.4.467     Document Type: Review

References (57)

1. Ohminam IH, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95(1), 286-293 (2000).
2. Azuma T, Makita M, Ninomiya K et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br. J. Haematol. 116(3), 601-603 (2002).
3. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59(11), 2675-2681 (1999).
4. Brossart P, Schneider A, Dill P et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61(18), 6846-6850 (2001).
5. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96(4), 1480-1489 (2000).
6. Gaiger A, Carter L, Greinix H et al. WT1-specific serum antibodies in patients with leukemia. Clin. Cancer Res. 7(3 Suppl.), 761s-765s (2001).
7. Savage P, Gao L, Vento K et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103(12), 4613-4615 (2004).
8. Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J. Immunol. 164(4), 1873-1880 (2000).
9. Mailander V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18(1), 165-166 (2004). The first published report on the clinical use of a WT-1 peptide vaccine in a patient with recurrent acute myeloid luekemia (AML), which demonstrated a clinical response to vaccination.
10. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885-13890 (2004).
11. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88(7), 2450-2457 (1996).
12. Brugger W, Schneider A, Schammann T et al. Dendritic cell-based vaccines in patients with hematological malignancies. Ann. NY Acad. Sci. 938, 359-362; discussion 362-353 (2001).
13. Greiner J, Ringhoffer M, Simikopinko O et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp. Hematol. 28(12), 1413-1422 (2000).
14. + T-cell line with potent in vivo graft-versus-leukemia properties. Blood 89(9), 3477-3485 (1997).
15. Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemiaassociated antigens. Blood 92(5), 1677-1684 (1998).
16. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271-296 (1991).
17. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767-811 (2000).
18. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104(8), 2235-2246 (2004).
19. Young JW, Steinman RM. The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells 14(4), 376-387 (1996).
20. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-α. J. Immunol. 154(11), 5851-5861 (1995).
21. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183(1), 317-322 (1996).
22. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1(12), 1297-1302 (1995).
23. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med.183(1), 283-287 (1996).
24. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392(6671), 86-89 (1998).
25. Spisek R, Chevallier P, Morineau N et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 62(10), 2861-2868 (2002).
26. O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immun. 52(6), 387-395 (2003).
27. Hirst WJ, Buggins A, Darling D et al. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther. 4(7), 691-699 (1997).
28. Hirano N, Takahashi T, Azuma M et al. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Hum. Gene Ther. 8(11), 1375-1384 (1997).
29. Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia 16(9), 1645-1654 (2002).
30. Orleans-Lindsay JK, Deru A, Craig JI, Prentice HG, Lowdell MW. In vitro co-stimulation with anti-CD28 synergizes with IL-12 in the generation of T cell immune responses to leukaemic cells; a strategy for ex vivo generation of CTL for immunotherapy. Clin. Exp. Immunol. 133(3), 467-475 (2003).
31. Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br. J. Haematol. 129(3), 340-349 (2005).
32. Gong J, Koido S, Kato Y et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res. 28(12), 1303-1312 (2004).
33. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immun. 51(6), 299-310 (2002).
34. Narita M, Takahashi M, Liu a et al. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia. Exp. Hematol. 29(6), 709-719 (2001).
35. Mohty M, Isnardon D, Blaise D et al. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 16(11), 2267-2274 (2002).
36. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur. J. Immunol. 29(8), 2567-2578 (1999). Among the first papers describing that patient-derived leukemic blasts can be differentiated into functionally active DCs.
37. Choudhury BA, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93(3), 780-786 (1999). Among the first papers describing that patient derived leukemic blasts can be differentiated into functionally active dendritic cells.
38. Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immuother. 24(7), 685-693 (2005).
39. Houtenbos I, Westers TM, Ossenkoppele GJ, Van de Loosdrecht AA. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica 91(3), 348-355 (2004).
40. Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by 'leukemic dendritic cells' derived from blast cells in acute myeloid leukemia. Blood 97(9), 2764-2771 (2001).
41. Westers TM, Stam AG, Scheper RJ et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol. Immun. 52(1), 17-27 (2003).
42. Robinson SP, English N, Jaju R et al. The in-vitro generation of dendritic cells from blast cells in acute leukaemia. Br. J. Haematol. 103(3), 763-771 (1998).
43. Woiciechowsky A, Regn S, Kolb HJ, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 15(2), 246-255 (2001).
44. Cignetti A, Bryant E, Allione B et al. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94(6), 2048-2055 (1999). Among the first papers describing that patient-derived leukemic blasts can be differentiated into functionally active DCs.
45. Cignetti A, Vallario A, Roato I et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J. Immunol. 173(4), 2855-2865 (2004).
46. Houtenbos I, Westers TM, Stam AG et al. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol. Immun. 52(7), 455-462 (2003).
47. Waclavicek M, Berer A, Oehler L et al. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br. J. Haematol. 114(2), 466-473 (2001).
48. Koski GK, Schwartz GN, Weng DE et al. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood 94(4), 1359-1371 (1999).
49. Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia 16(1), 84-93 (2002).
50. Vereecque R, Saudemont A, Depil S et al. Efficient generation of antileukemic autologous T cells by short-term culture and γ-irradiation of myeloid leukemic cells. Cancer Immunol. Immun. 53(9), 793-798 (2004).
51. + cytotoxic T cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-α. Mol. Ther. 11(6), 950-959 (2005).
52. Westers TM, Houtenbos I, Snoijs NC, Van de Loosdrecht AA, Ossenkoppele GJ. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity. Leukemia 19(7), 1270-1272 (2005).
53. Kufner S, Zitzelsberger H, Kroell T et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand. J. Immunol. 62(1), 86-98 (2005).
54. Kharfan-Dabaja M, Ayala E, Lindner I et al. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol. Immun. 54(1), 25-36 (2005).
55. Houtenbos I, Westers TM, De Gruijl TD et al. TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells. Leukemia 18(6), 1149-1153 (2004).
56. Li L, Giannopoulos K, Reinhardt P et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int. J. Oncol. 28(4), 855-861 (2006). The first published clinical trials describing the use of leukemia-derived DCs in patients with AML.
57. Roddie H, Klammer M, Thomas C et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br. J. Haematol. 133(2), 152-157 (2006). The first published clinical trials describing the use of leukemia-derived DCs in patients with AML.